ChemicalBook > CAS DataBase List > Zuberitamab
Zuberitamab
- Product Name
- Zuberitamab
- CAS No.
- 2251143-19-6
- Chemical Name
- Zuberitamab
- Synonyms
- Zuberitamab;Research Grade Zuberitamab;Research Grade Zuberitamab (DHC90719)
- CBNumber
- CB810617023
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
Zuberitamab Chemical Properties,Usage,Production
Uses
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma[1].
in vivo
Zuberitamab (0.1?mg/kg, intravenous injection, on day 0 and 10, 2 weeks) alone has no or minimal effect on tumor growth, when combined with BR105 results in significant inhibition of tumor growth with good anti-tumor efficacy in IRPα-humanized B-NDG mice tumor xenograft model[1].
References
[1] Zhen-Hua Wu, et al. Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint. J Immunother Cancer. 2022 Mar;10(3):e004054. DOI:10.1136/jitc-2021-004054
Zuberitamab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
Zuberitamab Suppliers
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58
- Tel
- 027-87008169 17762441161
- info@atagenix.com
- Country
- China
- ProdList
- 10001
- Advantage
- 58
- Tel
- 33175446423
- support@antibodysystem.com
- Country
- China
- ProdList
- 6739
- Advantage
- 58
- Tel
- 86-576-89007929
- Country
- CHINA
- ProdList
- 4
- Advantage
- 58
2251143-19-6, ZuberitamabRelated Search:
Trinbelimab
Tuvonralimab
Cergutuzumab Amunaleukin
Research Grade Clivatuzumab (DHD14205)
Xeligekimab
Sirtratumab
Teropavimab
Etevritamab
Demupitamab
Anumigilimab